×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Head & Neck Cancer

Alexandra Guadagno
From artificial intelligence to a surprise FDA resignation, check out this week’s quick overview of what is making headlines in the cancer space.
Gregory Carroll
A five-year lesson in cancer, worry and hope.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
 
Jessica Skarzynski
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
Katie Kosko
Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.
Katie Kosko
Immunotherapy may lead to a major change in how the treatment of metastatic recurrent head and neck cancer is approached, according to Barbara Burtness, M.D., a professor of medicine at Yale School of Medicine.
 
Kristie L. Kahl
Despite associated toxicities, cisplatin chemotherapy induced superior efficacy compared with a new alternative among patients with HPV-positive oropharyngeal carcinoma.
 
Jason M. Broderick
The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
Kristie L. Kahl and Mindy Waizer
Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.
Kathy LaTour
SCOTT WIESKAMP KNEW THE spot on his tonsil wasn’t normal.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other